DNLI Denali Therapeutics Inc.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Company profile
Ticker
DNLI
Exchange
Website
CEO
Ryan J. Watts
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • Gilead Sciences • Biogen • QIAGEN • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Allogene Therapeutics • Innate Pharma ...
SEC CIK
Corporate docs
DNLI stock data
()
Calendar
7 Aug 20
27 Sep 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 10 Sep 20 | Ho Carole | Common Stock | Sell | Dispose S | Yes | 31 | 3,689 | 114.36K | 165,141 |
| 21 Aug 20 | Krognes Steve E. | Common Stock | Payment of exercise | Dispose F | No | 32.87 | 1,954 | 64.23K | 1,006,511 |
| 21 Aug 20 | Schuth Alexander O. | Common Stock | Payment of exercise | Dispose F | No | 32.88 | 1,954 | 64.25K | 614,562 |
| 21 Aug 20 | Ho Carole | Common Stock | Payment of exercise | Dispose F | No | 32.88 | 1,954 | 64.25K | 6,511 |
| 20 Aug 20 | Krognes Steve E. | Common Stock | Option exercise | Aquire M | No | 0 | 5,643 | 0 | 1,008,465 |
| 20 Aug 20 | Krognes Steve E. | RSU Common Stock | Option exercise | Dispose M | No | 0 | 5,643 | 0 | 0 |
| 20 Aug 20 | Schuth Alexander O. | Common Stock | Option exercise | Aquire M | No | 0 | 5,643 | 0 | 616,516 |
| 20 Aug 20 | Schuth Alexander O. | RSU Common Stock | Option exercise | Dispose M | No | 0 | 5,643 | 0 | 0 |
| 20 Aug 20 | Ho Carole | Common Stock | Option exercise | Aquire M | No | 0 | 5,643 | 0 | 8,465 |
| 20 Aug 20 | Ho Carole | RSU Common Stock | Option exercise | Dispose M | No | 0 | 5,643 | 0 | 0 |
Institutional ownership Q2 2020
77.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 144 |
| Opened positions | 32 |
| Closed positions | 14 |
| Increased positions | 54 |
| Reduced positions | 35 |
13F shares |
Current |
|---|---|
| Total value | 2.13B |
| Total shares | 81.67M |
| Total puts | 13.3K |
| Total calls | 33.9K |
| Total put/call ratio | 0.4 |
Largest owners |
Shares | Value |
|---|---|---|
| Crestline Management | 13.64M | $329.93M |
| Baillie Gifford & Co | 9.28M | $224.37M |
| Flagship Pioneering | 7.98M | $192.96M |
| Vanguard | 7.09M | $171.34M |
| BLK BlackRock | 6.26M | $151.31M |
| FMR | 4.81M | $116.41M |
| Temasek | 4.41M | $106.65M |
| Gilder Gagnon Howe & Co | 3.39M | $81.86M |
| N Price T Rowe Associates | 2.62M | $63.4M |
| STT State Street | 2.25M | $54.29M |
Financial report summary
?Competition
Eisai • Mallinckrodt • Biogen • Astrazeneca • Roche • Shire • Cytokinetics • Sanofi • AbbVie • ProthenaRisks
- Risks Related to Our Business, Financial Condition and Capital Requirements
- Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
- Risks Related to Regulatory Approval and Other Legal Compliance Matters
- Risks Related to Our Reliance on Third Parties
Management Discussion
- Collaboration revenue was $5.8 million and $9.5 million for the three and six months ended June 30, 2020, respectively, and $4.2 million and $8.4 million for the three and six months ended June 30, 2019, respectively. The increases in collaboration revenue of $1.6 million and $1.1 million for the three and six months ended June 30, 2020, respectively, compared to the comparative period in the prior year were due to increases in revenue from our collaboration with Takeda, driven by increased costs incurred in the programs partnered with Takeda, partially offset by decreases in revenue from our collaboration with Sanofi driven by the fact that revenue for retained activities under the Sanofi Collaboration Agreement are winding down as activities are transferred to Sanofi.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Abeta, adult, antitrust, beta, chronic, customary, death, description, displayed, elderly, encouraging, eukaryotic, heightening, infected, infection, lung, MA, opt, presence, regular, remotely, responding, sixteen, slowdown, sporadic, switching, translation, unique, uptake
Removed:
achieved, administrator, amyotrophic, attribution, automatically, Carlo, commitment, consecutive, dividend, emerging, equal, financed, half, intrinsic, lattice, Monte, overlapping, payroll, preceding, recipient, revalued, scheduled, simplified, simulation, stepped, unamortized, unissued, unvested, vested, vesting
Financial reports
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
12 Mar 19
10-Q/A
2018 Q2
Quarterly report (amended)
6 Dec 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
Current reports
8-K
Departure of Directors or Certain Officers
20 Aug 20
8-K/A
Submission of Matters to a Vote of Security Holders
20 Aug 20
8-K
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
7 Aug 20
8-K
Entry into a Material Definitive Agreement
6 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 20
8-K
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
7 May 20
8-K
Denali Therapeutics Provides Pipeline and Business Update In Response to the COVID-19 Pandemic
2 Apr 20
8-K
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
27 Feb 20
8-K
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
29 Jan 20
8-K
Denali Therapeutics Announces Proposed Offering of Common Stock
27 Jan 20
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 20
424B5
Prospectus supplement for primary offering
29 Jan 20
424B5
Prospectus supplement for primary offering
27 Jan 20
S-3ASR
Automatic shelf registration
13 Mar 19
S-8
Registration of securities for employees
13 Mar 19
424B4
Prospectus supplement with pricing info
8 Dec 17
S-8
Registration of securities for employees
8 Dec 17
S-1/A
IPO registration (amended)
7 Dec 17
8-A12B
Registration of securities on exchange
30 Nov 17
S-1/A
IPO registration (amended)
27 Nov 17
Other
UPLOAD
Letter from SEC
7 Oct 19
CORRESP
Correspondence with SEC
11 Sep 19
UPLOAD
Letter from SEC
16 Aug 19
CORRESP
Correspondence with SEC
16 Jul 19
UPLOAD
Letter from SEC
2 Jul 19
CT ORDER
Confidential treatment order
25 Mar 19
CT ORDER
Confidential treatment order
21 Feb 19
CT ORDER
Confidential treatment order
19 Nov 18
CT ORDER
Confidential treatment order
17 Jul 18
CT ORDER
Confidential treatment order
8 Dec 17
Ownership
4
Denali Therapeutics / Carole Ho ownership change
15 Sep 20
4
Denali Therapeutics / Carole Ho ownership change
25 Aug 20
4
Denali Therapeutics / Alexander O. Schuth ownership change
25 Aug 20
4
Denali Therapeutics / Steve E. Krognes ownership change
25 Aug 20
4
Denali Therapeutics / Carole Ho ownership change
20 Aug 20
4
Denali Therapeutics / Alexander O. Schuth ownership change
20 Aug 20
4
Denali Therapeutics / Steve E. Krognes ownership change
20 Aug 20
4
Denali Therapeutics / Ryan J. Watts ownership change
20 Aug 20
4
Denali Therapeutics / DOUGLAS K BRATTON ownership change
14 Aug 20
4
Denali Therapeutics / DOUGLAS K BRATTON ownership change
30 Jun 20
Patents
APP
Utility
Affinity-based Methods for Using Transferrin Receptor-binding Proteins
17 Sep 20
Provided herein are methods for transporting agents across the blood brain barrier.
APP
Utility
ANTI-TREM2 Antibodies and Methods of Use Thereof
3 Sep 20
In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided.
APP
Utility
Fusion Proteins Comprising Enzyme Replacement Therapy Enzymes
3 Sep 20
Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder.
APP
Utility
Engineered Polypeptides
20 Aug 20
Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB.
APP
Utility
Engineered Transferrin Receptor Binding Polypeptides
16 Jul 20
Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.